Tirzepatide
Dual GIP/GLP-1 Receptor Agonist | Weight Reduction & Diabetes
On this page
What is Tirzepatide?
Tirzepatide is a lab-made peptide that activates two different gut-hormone receptors (GIP and GLP-1) instead of just one, which is why researchers call it a dual agonist. It's the active ingredient behind FDA-approved diabetes and weight-management medications, and is one of the most heavily studied metabolic peptides in the clinical literature. Research-grade tirzepatide sold here is intended for laboratory research use only — it is not the same product as, and is not a substitute for, an approved prescription medication.
Key terms:
Tirzepatide is a dual glp-1/gip receptor agonist (glp-1 + gip dual agonist).
Tirzepatide is a lab-made peptide that acts on two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Both are incretin hormones, the body's own signals for handling blood sugar after a meal. The FDA has approved it for type 2 diabetes and for chronic weight management. In clinical trials researchers reported substantial weight reduction and improvement in metabolic health markers. The reported mechanism: steadier blood sugar control, slower gastric emptying, and reduced appetite. Trials also reported greater effects than single-mechanism GLP-1 agonists.
Key research areas
- Dramatic weight reduction (15-22% body weight)
- Diabetes control studied in clinical trials
- Reduced cardiovascular risk
- Improved insulin sensitivity
- Appetite suppression
- Preserved muscle mass
Researched dosing
This table reflects how researchers structure tirzepatide study designs — the titration schedules and dose ranges used in published trials, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Weight-reduction studies — starting | 2.5mg weekly | Once weekly | SubQ injection |
| Weight-reduction studies — mid step | 5mg weekly | Once weekly | SubQ injection |
| Weight-reduction studies — later step | 7.5-10mg weekly | Once weekly | SubQ injection |
| Weight-reduction studies — highest step | 12.5-15mg weekly | Once weekly | SubQ injection |
| Diabetes studies (mild) | 5-7.5mg weekly | Once weekly | SubQ injection |
| Diabetes studies (severe) | 10-15mg weekly | Once weekly | SubQ injection |
Commonly cycled 24 weeks on, 0+ weeks off.
How it works
At the cell level, tirzepatide research looks at how the peptide binds both GIP and GLP-1 receptors to influence insulin release, digestion speed, and appetite signaling — the terms below are just the names for those cell-signaling steps.
Dual agonist of the GIP and GLP-1 incretin receptors — engaging the GIP receptor on top of GLP-1 is its defining feature versus single GLP-1 agonists. Drives glucose-dependent insulin stimulation, gastric emptying delay, glucagon suppression, and central satiety signaling through hypothalamic pathways.
Molecular data
These figures — molecular weight, amino-acid sequence, chain length — are the chemistry basics researchers and lab technicians use to confirm a tirzepatide sample's identity and purity before it goes into a study.
- Weight
- 4813.55 Da
- Length
- 39 amino acids
- Type
- Dual GLP-1/GIP agonist
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys
Pharmacokinetics
This chart plots how long a research dose of tirzepatide stays active in the literature — its multi-day clearance curve is part of why the FDA-approved medication built on this compound uses once-weekly dosing.
- Peak
- 24 hr
- Half-life
- 120 hrs
- Cleared
- ~600 hrs
FDA Mounjaro Label
Research applications
This section lists the research areas — metabolic and diabetes research chief among them — that scientists have studied for tirzepatide in the clinical literature; research-grade tirzepatide sold here is intended for laboratory study only, not human use.
Weight Reduction
Clinical trials report 15-22% body weight reduction in non-diabetic obese individuals - greater than other weight-reduction medications studied, including semaglutide. Trials also report improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers, with preferential reduction of visceral adipose tissue while preserving lean muscle mass when combined with resistance training and adequate protein.
Diabetes
Effective management of type 2 diabetes with significant improvements in cardiometabolic parameters and blood glucose control.
Cardiovascular
Moderate cardiovascular benefits demonstrated in clinical trials with reduction in major adverse cardiovascular events.
Dosage reference
- Doses used in research
- Published trials started at 2.5 mg once weekly, raising the dose about once a month toward the maintenance dose.
- Frequency in studies
- Same day each week, any time of day
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Appetite reduction 1-3 days, weight reduction 2-4 weeks, peak effects 12-20 weeks
- Storage
- Refrigerate 2-8°C, never freeze, protect from light
- Cycle length
- 12-24+ weeks minimum for full metabolic benefits
- Break between cycles
- Medical supervision required for discontinuation
Interactions
This list shows which other metabolic-research peptides scientists study alongside tirzepatide, and flags pairings that call for extra caution or monitoring in a research setting.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried tirzepatide powder into a liquid research solution — the same basic water-based mixing process used for most peptide research.
- Remove tirzepatide vial from refrigerator and allow to reach room temperature for 15-20 minutes to prevent condensation
- Clean vial tops with alcohol wipes using circular motion from center outward, allow to air dry completely
- Calculate appropriate reconstitution volume based on desired concentration using the calculator below
- Draw calculated amount of bacteriostatic water into insulin syringe, ensuring no air bubbles
- Insert needle into tirzepatide vial at 45-degree angle against the glass wall, NOT directly into powder
- Slowly inject BAC water down the side of the vial - inject drop by drop to avoid foaming or protein degradation
- Remove needle and gently swirl vial in circular motion - NEVER shake vigorously as this destroys the protein
- Allow solution to sit for 2-3 minutes if any cloudiness persists, then swirl gently again until completely clear
- Final solution should be completely clear and colorless - any persistent cloudiness indicates degradation
- Label vial with reconstitution date and concentration
- Use within 28 days of reconstitution, inspect for particles before use
Lyophilized: 2-8°C, use within Per manufacturer expiration date
Reconstituted: 2-8°C, use within 28 days
Open the Tirzepatide reconstitution calculatorQuality indicators
These are the visual and lab-report checks researchers use to confirm a tirzepatide sample is pure and correctly identified before it goes into a study — a quick sanity check against the Certificate of Analysis (COA), not a guarantee.
White to off-white lyophilized powder - Properly freeze-dried tirzepatide appears as light, fluffy powder cake without clumping
Clear reconstituted solution - Should be completely clear and colorless after proper reconstitution - no particles or cloudiness
Intact vial seal and proper labeling - Rubber stopper should be intact, clear mg dosage labeling, batch numbers, and expiration dates visible
Proper storage maintenance - Stored at correct temperature (2-8°C), protected from light, never frozen or overheated
Clumping, discoloration, or moisture - Powder should not be clumped, yellow/brown colored, or show signs of moisture damage or melting
Persistent cloudiness after reconstitution - Cloudiness that doesn't clear after proper mixing indicates protein aggregation or contamination
Unusual crystallization patterns - Large crystals or unusual formations may indicate storage temperature fluctuations or degradation
What to expect
This timeline reflects what the clinical literature reports at each study stage — research context for comparing studies, not a personal-results promise.
Appetite reduction within 1-3 days of first injection
Mild to moderate nausea for first 2-4 weeks (typically improves significantly). 1-3 lbs weight reduction per week during active weight reduction phase. Improved blood sugar control within 1-2 weeks for diabetics. Dramatically reduced food cravings and smaller portion satisfaction. Better satiety and meal satisfaction lasting 6-7 days per injection. Possible fatigue during initial adaptation weeks.
Peak weight reduction effects typically seen at 16-24 weeks. Improved energy levels after initial adaptation period.
Safety notes
This section summarizes tirzepatide's regulatory status and handling notes — contraindication and safety data drawn from the clinical literature on the FDA-approved medication, provided here as reference context for laboratory researchers, not medical guidance.
- Contraindicated with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- Monitor for signs of acute pancreatitis (severe, persistent abdominal pain radiating to the back)
- Requires prescription and medical supervision - not available over-the-counter
- May require adjustment of other diabetes medications to prevent hypoglycemia
- FDA-approved for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)
- Requires prescription and medical supervision
Regulatory status
- Approved by the FDA for at least one indication. That approval applies to regulated pharmaceutical products, not to research-grade material.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
Frequently asked questions
What is Tirzepatide?
Tirzepatide is a lab-made peptide that activates two different gut-hormone receptors — GIP and GLP-1 — instead of just one, which is why researchers call it a dual agonist. It is one of the most heavily studied metabolic peptides in the clinical literature. Lux BioPure supplies research-grade tirzepatide strictly for laboratory study; it is not for use in people or animals and is not a substitute for an approved medication.
What class of compound is tirzepatide?
Tirzepatide is classified as a dual GLP-1/GIP receptor agonist — it binds both the GIP and GLP-1 receptor families, a broader activation pattern than single-receptor compounds. In the research literature this dual-agonist chemistry is characterized by a molecular weight near 4,814 daltons and a 39-residue chain, figures lab technicians use to confirm a sample's identity before study.
How is tirzepatide typically reconstituted for research use?
In the laboratory, a tirzepatide vial is first brought to room temperature and its stopper cleaned with an alcohol wipe. Bacteriostatic water is then injected slowly down the vial wall — not onto the powder — and the vial is gently swirled, never shaken, until the solution is completely clear and colorless. This is standard peptide-handling methodology, not a usage instruction.
How should tirzepatide be stored in the lab?
Lyophilized tirzepatide is kept refrigerated at 2–8°C, protected from light and never frozen or overheated. Once reconstituted with bacteriostatic water, the solution is refrigerated at 2–8°C and typically used within about 28 days, with the vial labeled by date and concentration. A good sample appears as a white, fluffy powder cake that forms a clear, particle-free solution.
Is tirzepatide legal to purchase for research in Canada?
Lux BioPure sells tirzepatide in Canada strictly as a research-use-only chemical for laboratory study — it is not for human or veterinary use and is not offered as a drug or supplement. Approved prescription medications are built on this compound, but the research-grade material supplied here is a distinct product and is not a substitute for an approved medication.
References
15mg dose achieved 15.7% weight reduction with significant improvements in all cardiometabolic parameters in 938 adults with T2DM and obesity
View Study26% reduction in major adverse cardiovascular events in 12,785 T2DM patients, establishing cardioprotective benefits
15mg weekly dose achieved 22.5% weight reduction vs 2.4% placebo - largest weight reduction seen in pharmaceutical trials (2,539 adults with obesity)
View Study